245 related articles for article (PubMed ID: 32312780)
21. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
[TBL] [Abstract][Full Text] [Related]
22. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Song JY; Noh JY; Choi WS; Cheong HJ; Kim WJ
Expert Rev Anti Infect Ther; 2015; 13(11):1361-72. PubMed ID: 26256778
[TBL] [Abstract][Full Text] [Related]
23. Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
Ma C; Li F; Musharrafieh RG; Wang J
Antiviral Res; 2016 Sep; 133():62-72. PubMed ID: 27478032
[TBL] [Abstract][Full Text] [Related]
24. BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses.
Shih SR; Horng JT; Poon LL; Chen TC; Yeh JY; Hsieh HP; Tseng SN; Chiang C; Li WL; Chao YS; Hsu JT
J Antimicrob Chemother; 2010 Jan; 65(1):63-71. PubMed ID: 19892833
[TBL] [Abstract][Full Text] [Related]
25. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
Pires de Mello CP; Drusano GL; Adams JR; Shudt M; Kulawy R; Brown AN
Eur J Pharm Sci; 2018 Jan; 111():443-449. PubMed ID: 29079337
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
27. The use of antiviral agents for the management of severe influenza.
Smith JR; Ariano RE; Toovey S
Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416
[TBL] [Abstract][Full Text] [Related]
28. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Dixit R; Khandaker G; Ilgoutz S; Rashid H; Booy R
Infect Disord Drug Targets; 2013 Feb; 13(1):34-45. PubMed ID: 23675925
[TBL] [Abstract][Full Text] [Related]
29. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
30. Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
Dharan NJ; Beekmann SE; Fiore A; Finelli L; Uyeki TM; Polgreen PM; Fry AM
Antiviral Res; 2010 Nov; 88(2):182-6. PubMed ID: 20739002
[TBL] [Abstract][Full Text] [Related]
31. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of influenza virus replication by plant-derived isoquercetin.
Kim Y; Narayanan S; Chang KO
Antiviral Res; 2010 Nov; 88(2):227-35. PubMed ID: 20826184
[TBL] [Abstract][Full Text] [Related]
33. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
Pizzorno A; Abed Y; Rhéaume C; Boivin G
Antiviral Res; 2014 May; 105():54-8. PubMed ID: 24583158
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
35. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
[TBL] [Abstract][Full Text] [Related]
36. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
39. Aronia melanocarpa and its components demonstrate antiviral activity against influenza viruses.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Han SZ; Park MS
Biochem Biophys Res Commun; 2013 Oct; 440(1):14-9. PubMed ID: 24012672
[TBL] [Abstract][Full Text] [Related]
40.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
